Hospitalists are being urged to rethink how they treat alcohol withdrawal and alcohol use disorder, moving toward less stigmatizing language and more proactive use of medication during a hospital stay. The approach, outlined in a recent session, focuses on better risk stratification, improved monitoring tools, and a consistent offer of long-term treatment while patients are still in the hospital.
About half of individuals with unhealthy alcohol use experience some degree of withdrawal. But roughly 80% of those cases are uncomplicated and not life-threatening, according to it. The other 5% to 20% involve seizures, hallucinations, or delirium tremens — the so-called DTs.
Repeated withdrawal episodes can trigger kindling, where each episode makes the next one more severe.
Related: Converge 2026 Highlights Skin’s Role in Inpatient Dermatology
Identifying high-risk patients early matters.
The Prediction of Alcohol Withdrawal Severity Scale, or PAWSS, was highlighted as a highly accurate tool. A score of 4 or more signals a high risk for severe withdrawal and should prompt early, aggressive treatment.
Monitoring symptoms is also evolving. The Clinical Institute Withdrawal Assessment for Alcohol, or CIWA, has long been the standard, but it has limitations. More than half of hospitalized individuals are evaluated with it unnecessarily, and the tool is subjective, requiring frequent nursing checks.
The modified Minnesota Detoxification Scale, or mMINDS, is a more objective and efficient alternative. It has been validated in emergency, intensive care, and general medicine settings and may reduce benzodiazepine use and mechanical ventilation rates. But doctors need to be careful — vital sign problems from other conditions can inflate the score.
Related: Teachers add heat to lessons with quick creativity
Benzodiazepines remain the gold standard for treating withdrawal itself, acting on GABA receptors to calm the hyperexcitable state. Long-acting agents like diazepam are preferred. Symptom-triggered dosing works for most people, though front-loading is recommended for severe cases.
Phenobarbital is increasingly used as an adjunct or alternative in severe withdrawal. Its dual mechanism — enhancing GABA and blocking NMDA receptors — makes it effective even when benzodiazepines are not enough. Studies suggest it can reduce ICU admissions and shorten hospital stays. But its narrow therapeutic window requires careful dosing.
Every individual should receive IV thiamine for three to five days to prevent Wernicke encephalopathy. Routine checks of magnesium, liver function, and urine drug screens are also advised.
